Molecule
Progesterone is a progesterone indicated for progesterone supplementation or replacement as part of an Assisted Reproductive Technology ("ART") treatment for infertile women with progesterone deficiency, among other approved uses. MedsAcross supplies Progesterone for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
Assisted Reproductive Technology Crinone 8% is indicated for progesterone supplementation or replacement as part of an Assisted Reproductive Technology ("ART") treatment for infertile women with progesterone deficiency. Secondary Amenorrhea Crinone 4% is indicated for the treatment of secondary amenorrhea. Crinone 8% is indicated for use in women who have failed to respond to treatment with Crinone 4%.
Source: US FDA prescribing information
Assisted Reproductive Technology Crinone 8% is administered vaginally at a dose of 90 mg once daily in women who require progesterone supplementation. Crinone 8% is administered vaginally at a dose of 90 mg twice daily in women with partial or complete ovarian failure who require progesterone replacement. If pregnancy occurs, treatment may be continued until placental autonomy is achieved, up to 10 to 12 weeks. Secondary Amenorrhea Crinone 4% is administered vaginally every other day up to a total of six doses. For women who fail to respond, a trial of Crinone 8% every other day up to a total of six doses may be instituted. It is important to note that a dosage increase from the 4% gel can only be accomplished by using the 8% gel. Increasing the volume of gel administered does not increase the amount of progesterone absorbed.
Source: US FDA prescribing information
Crinone should not be used in individuals with any of the following conditions: Known sensitivity to Crinone (progesterone or any of the other ingredients) Undiagnosed vaginal bleeding Liver dysfunction or disease Known or suspected malignancy of the breast or genital organs Missed abortion Active thrombophlebitis or thromboembolic disorders, or a history of hormone-associated thrombophlebitis or thromboembolic disorders
Source: US FDA prescribing information
The physician should be alert to the earliest manifestations of thrombotic disorders (thrombophlebitis, cerebrovascular disorders, pulmonary embolism, and retinal thrombosis). Should any of these occur or be suspected, the drug should be discontinued immediately. Progesterone and progestins have been used to prevent miscarriage in women with a history of recurrent spontaneous pregnancy losses. No adequate evidence is available to show that they are effective for this purpose.
Source: US FDA prescribing information
Assisted Reproductive Technology In a study of 61 women with ovarian failure undergoing a donor oocyte transfer procedure receiving Crinone 8% twice daily, treatment-emergent adverse events occurring in 5% or more of the women are shown in Table 3. TABLE 3 Treatment-Emergent Adverse Events in ≥ 5% of Women Receiving Crinone 8% Twice Daily Study COL1620-007US (n = 61) Body as a Whole Bloating 7% Cramps NOS 15% Pain 8% Central and Peripheral Nervous System Dizziness 5% Headache 13% Gastro-Intestinal System Nausea 7% Reproductive, Female Breast Pain 13% Moniliasis Genital 5% Vaginal Discharge 7% Skin and Appendages Pruritus Genital 5% In a second clinical study of 139 women using Crinone 8% once daily for luteal phase support while undergoing an in vitro fertilization procedure, treatment-emergent adverse events reported in ≥ 5% of the women are shown in Table 4.
Source: US FDA prescribing information
No drug interactions have been assessed with Crinone.
Source: US FDA prescribing information
Store at 20-25ºC (68-77ºF).
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
12 presentations of Progesterone, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Progesterone 100 mg capsuleOralGeneric name | — | US FDA | Available on request |
| Progesterone 200 mg capsuleOralGeneric name | — | US FDA | Available on request |
| Progesterone 500 mg/10 mL injectionIntramuscularGeneric name | — | US FDA | Available on request |
| Progesterone 100 mg vaginal insertVaginalGeneric name | — | US FDA | Available on request |
| Crinone 4% vaginal gelVaginal | Allergan | US FDA | Available on request |
| Crinone 8% vaginal gelVaginal | Allergan | US FDA | Available on request |
| Endometrin 100 mg vaginal insertVaginal | Ferring Pharmaceuticals | US FDA | Available on request |
| Progesterone 50 mg injectionIntramuscularGeneric name | — | US FDA | Available on request |
| Progesterone vaginal insert 100 mg vaginal insertVaginal | Xiromed | US FDA | Available on request |
| Progesterone Vaginal Inserts 100 mg vaginal insertVaginal | Glenmark PharmaceuticalsIndia | US FDA | Available on request |
| Prometrium 100 mg capsuleOral | Acertis Pharmaceuticals | US FDA | Available on request |
| Prometrium 200 mg capsuleOral | Acertis Pharmaceuticals | US FDA | Available on request |
5 brand names across 1 markets.
Indian manufacturers are highlighted.
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 1 November 1974 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Conditions linked to Progesterone in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 12 presentations of Progesterone and sources them for licensed hospitals, importers and physicians against valid import documents. Indian manufacturers include Glenmark Pharmaceuticals.
The catalogue lists 5 brand names for Progesterone, including Crinone, Endometrin, Progesterone vaginal insert, Progesterone Vaginal Inserts, Prometrium.
Yes. The US FDA first approved Progesterone on 1 November 1974, according to Drugs@FDA.
No listed presentation of Progesterone is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Progesterone is classified under ATC code G03DA04 (Progesterone).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.